AMAG Pharma (AMAG): Low Expectations Shift The Risk Reward To The Upside - Jefferies
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) noting that the Makena franchise (~60% of current revenue) has been disappointing since 3Q15 on missed sales/delays in line-extension strategies. The current share price abundantly reflects such frustration and assumes that Makena & Feraheme sales are going to zero following 02/18 & 06/23 exclusivity expiry. That may turn out to be the case or it may take a while for AMAG to regain investors' confidence but the analyst thinks that the risk/reward seems skewed to the upside .
The price target drops to $45.00 from $58.00 but reflects substantial upside from the current price of $25.51.
Shares of AMAG Pharmaceuticals closed at $22.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
- Sprint (S) PT Raised to $4.50 at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!